otrivin 1 mg/ ml
haleon denmark aps - xylometazolinhydroklorid - nesespray, oppløsning - 1 mg/ ml
otrivin comp 0.5 mg/ ml / 0.6 mg/ ml
haleon denmark aps - xylometazolinhydroklorid / ipratropiumbromid - nesespray, oppløsning - 0.5 mg/ ml / 0.6 mg/ ml
benefix
pfizer europe ma eeig - nonacog alfa - hemofili b - antihemoragika - behandling og profylakse av blødninger hos pasienter med haemophilia b (medfødt faktor-ix-mangel).
afipran 10 mg
orifarm healthcare a/s - metoklopramidhydroklorid - tablett - 10 mg
afipran 5 mg/ ml
orifarm healthcare a/s - metoklopramidhydroklorid - injeksjonsvæske, oppløsning - 5 mg/ ml
afipran 1 mg/ ml
orifarm healthcare a/s - metoklopramidhydroklorid - mikstur, oppløsning - 1 mg/ ml
metoclopramide orifarm 10 mg
orifarm generics a/s - metoklopramidhydrokloridmonohydrat - tablett - 10 mg
metoclopramide accord 10 mg
accord healthcare b.v. - metoklopramidhydrokloridmonohydrat - tablett - 10 mg
vectibix
amgen europe b.v. - panitumumab - colorektale neoplasmer - antineoplastiske midler - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. i andre linje i kombinasjon med folfiri for pasienter som har mottatt første-linje fluoropyrimidine-basert kjemoterapi (med unntak av irinotecan). som monoterapi etter svikt av fluoropyrimidine-, oxaliplatin-og irinotecan-inneholder kjemoterapi regimer.
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.